Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00562107 · ClinicalTrials.gov registry record · Phase 4
Evaluation of the SafeR Mode in Patients With a Dual Chamber Pacemaker Indication
A Phase 4 study, sponsored by LivaNova.
- Completed
- Registry status
- Phase 4
- Development phase
- 650
- Enrollment target
NCT00562107: Completed Phase 4 study, sponsored by LivaNova.
NCT00562107 is a Phase 4 study that has completed, run by LivaNova. The registered enrollment target is 650 participants, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (25% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00562107, a Phase 4 study, has completed, sponsored by LivaNova.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 650 participants
- Enrollment target
Study Summary
The aim of this study is to assess the benefits from the AAISafeR/SafeR algorithm of Symphony 2550 or REPLY DR in a wide range of pacemaker patients. The expected benefits will be a result of the reduction of the percentage of ventricular pacing. It contributes to the longevity of the cardiac pacemaker and has an effect on the incidence of sustained (or persistent) Atrial Fibrillation and Heart Failure. These clinical benefits are a result of spontaneous ventricular activation which ensures a more physiological ventricular activation. The benefits will be assessed by comparing the incidence of atrial arrhythmias and the evolution of the haemodynamic status of the patients (QOL, echo and BNP)
Interventions
- DEVICE Symphony DR 2550 and REPLY DR cardiac pacemakers
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 650 participants |
| Start Date | 2007-12 |
| Est. Completion | 2013-04 |
| Phase | Phase 4 |
What the finished NCT00562107 record still lists
NCT00562107 is an interventional study that assigns participants to a tested intervention. The registered 650 participants enrollment target is mid-sized for trials with a published cap, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (25% higher).
The record links to 0 conditions, and to 1 intervention - of which Symphony DR 2550 and REPLY DR cardiac pacemakers is the first listed.
NCT00562107 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00562107 about?
NCT00562107 is a clinical study titled "Evaluation of the SafeR Mode in Patients With a Dual Chamber Pacemaker Indication". The aim of this study is to assess the benefits from the AAISafeR/SafeR algorithm of Symphony 2550 or REPLY DR in a wide range of pacemaker patients. The expected benefits will be a result of the reduction of the percentage of ventricular pacing. It contributes to the longevity of the cardiac pace...
What is the current status of trial NCT00562107?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 650 participants. The study started on 2007-12. Estimated completion is 2013-04.
What interventions are being tested in trial NCT00562107?
The interventions under investigation include: Symphony DR 2550 and REPLY DR cardiac pacemakers (DEVICE).
Who is sponsoring clinical trial NCT00562107?
This trial is sponsored by LivaNova, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00562107's enrollment target sits among peer trials
650 122nd of 2000 higher than 1,877 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02934477 · 650 participants
Prospective Assessment of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis
- NCT04579120 · 650 participants
Neuroimaging in Healthy Aging and Senile Dementia (HASD_IND)
- NCT04875702 · 650 participants · Phase 4
Treat-to-Target Serum Urate Versus Treat-to-Avoid Symptoms in Gout
- NCT05046600 · 650 participants
Registry of Arthrex Hand and Wrist Products
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia